# A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

> **NCT07005336** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **TJ Biopharma Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Uliledlimab
- **DRUG:** Sintilimab
- **DRUG:** Pemetrexed
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin Or Carboplatin

## Key facts

- **NCT ID:** NCT07005336
- **Lead sponsor:** TJ Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-09
- **Primary completion:** 2026-08-30
- **Final completion:** 2029-01-09
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07005336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07005336, "A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07005336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*